An epidemiologic study on PD-L1 expression combined with clinical observation in the Chinese MIUBC patients.

Trial Identifier:	D9012R00001
Sponsor:	AstraZeneca
NCTID::	NCT03433924
Start Date:	May 2020
Primary Completion Date:	March 2023
Study Completion Date:	March 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Beijing, China, 100034
China	Beijing, China, 100730
China	Changchun, China, 130021
China	Changsha, China, 410013
China	Chengdu, China, 610041
China	Guangzhou, China, 510120
China	Guangzhou, China, 510060
China	Hangzhou, China, 310014
China	Jinan, China, 250012
China	Meizhou, China
China	Nanjing, China, 2100008
China	Shanghai, China, 200032
China	Shanghai, China, 200072
China	Shenyang, China, 110001
China	Wuhan, China, CN-430030
China	Xiamen, China, 361003
China	Zhengzhou, China, 450052

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company